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The use of pharmacological agents is often the preferred approach to the management of
vestibular dysfunction. In the vestibular sensory pathways, the sensory neuroepithelia are
thought to be influenced by a diverse number of neuroactive substances that may act to
enhance or inhibit the effect of the primary neurotransmitters [i.e., glutamate (Glu) and acetylcholine (ACh)] or alter their patterns of release. This review summarizes various efforts to
identify drug targets including neurotransmitter and neuromodulator receptors in the vestibular sensory pathways. Identifying these receptor targets provides a strategic basis to use
specific pharmacological tools to modify receptor function in the treatment and management of debilitating balance disorders. A review of the literature reveals that most investigations of the neuropharmacology of peripheral vestibular function have been performed using in vitro or ex vivo animal preparations rather than studying drug action on the normal
intact vestibular system in situ. Such noninvasive approaches could aid the development of
more accurate and effective intervention strategies for the treatment of dizziness and vertigo. The current review explores the major neuropharmacological targets for drug action in
the vestibular system.
J Audiol Otol 2017;21(3):125-132
KEY WORDS:0Dizziness · Vertigo · Peripheral vestibular system · Neuroactive substance ·
Vestibular suppressant.

Introduction
Dizziness may be caused by many disturbances in central
and peripheral neural function. Vertigo, dizziness, and disequilibrium consistently rank among the most common complaints experienced by individuals with vestibular dysfunction. Moreover, vestibular deficits appear to be among the most
common causes of dysequilibrium symptoms requiring medical intervention. Decreased function of the peripheral vestibular system can result in decreased visual acuity during head
movements and a degradation of postural control. The management of dizziness related symptoms has mostly involved
the use of pharmacological agents during the early acute
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.

phase of symptom onset. The common objective of drug treatment is to suppress vestibular sensory input. This is thought to
reduce conflicting sensory input, control undesirable perceptions, and improve the quality of life of patients.
Vestibular signals originate from the sensory organs of the
three semicircular canals and two macular organs within the
petrous portion of the temporal bone (Fig. 1). The vestibular
neuroepithelium including hair cells, supporting cells as wells
as afferent and efferent neurons are thought to interact with a
diverse number of neuroactive substances (neurotransmitters
and neuromodulators), which bind to specific receptors at the
postsynaptic membrane. During normal chemical synaptic
transmission, these neurotransmitters and modulators are synthesized and stored in presynaptic vesicles and are released into
the synapse to bind and act on postsynaptic cell receptors during the transmission and processing of sensory information.
Glutamate [Glu or a glutamate-like excitatory amino acid
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(EAA)] and acetylcholine (ACh) are widely accepted as being the primary neurotransmitters released by vestibular hair
cells and efferent neural terminals respectively [1,2]. In the
peripheral vestibular system, there are a variety of other neuroactive molecules that are thought to be present and may act
as modulators at these synapses including γ-amino butyric
acid (GABA), substance P, calcitonin gene-related protein
(CGRP), and opioid peptides. These neuromodulators may
affect the response of neurons by facilitating or inhibiting the
effect of the primary neurotransmitters or by altering patterns
of release. Neuroactive substances bind with numerous corresponding postsynaptic and presynaptic receptors to mediate neural transmission or modulate the response of postsynaptic neurons. Pharmacologic agents can act at these receptors
to alter synaptic messaging. In this way, pharmacological
agents have a diverse array of cellular targets that provide a
means for modifying sensory transmission. In Fig. 2, many of
the possible targets of pharmacological agents in the peripheral vestibular sensory neuroepithelium are summarized.

Macula

Fig. 1. Schematic illustration of the
vestibular end organ (top), which
includes the neuroepithelium of the
crista ampullaris (lower left) and
vestibular macula (lower right). The
membranous labyrinth is fluid-filled
with endolymph (blue color on top
panel) and perilymph (red color). The
vestibular system is composed of
five organs; three semicircular canals
also called “crista sensors” to detect
angular accelerations of the head
and two otolith organs also called
“macular sensors” to detect the linear acceleration of the head. In the
crista, kinocilia and stereociliary bundles of hair cells extend into the gelatinous cupula. During angular acceleration of the head, surrounding
endolymph lags and moves in the
opposite direction in response to rotational acceleration. In the macula,
dense calcium carbonate (called
“otoconia”) are embedded within the
otoconial layer, which is greater density than surrounding fluid and tissues of the maculae. During linear
acceleration of the head, high density of otoconial layer causes the otoconial layer to shift position relative
to the neuroepithelium producing a
movement of stereociliary bundles
of receptor hair cells.

Neuroactive Substances and
Receptors
Molecular biological, biochemical, and electrophysiological evidences suggest that glutamate, ACh, histamine, enkephalins, GABA, CGRP, and substance P are all released to
some extent as neurotransmitters or modulators in the peripheral vestibular system [3,4]. In central vestibular circuits, the
vestibular nuclei integrate vestibular, somatosensory, proprioceptive, and visual inputs. These diverse synaptic inputs
to the nuclei are also represented by glutamatergic, GABAergic, histaminergic, serotoninergic, and dopaminergic neurons
[4]. These neural projections to vestibular nuclei arise mainly
from vestibular afferent neurons, spinal afferents, cerebellum,
and more rostral descending visual and motor control systems
[5]. The following provides an overview of neurotransmitter
and neuromodulator receptors identified in the peripheral vestibular neuroepithelium and ganglion as well as in central vestibular nuclei.
Glutamate receptors
In the vestibular system, glutamate is an EAA and the major neurotransmitter of the vestibular sensory hair cells [1].

126

J Audiol Otol 2017;21(3):125-132

Lee C, et al.

Endolymph

Perilymph

Type II
Type I

hair cell

hair cell
mACh,
nACh,
GABAA-B,

AMPA,

AMPA,

CGRP,

NMDA,

NMDA,

Enkephalin,

KA,

KA,

Substance P

H3-4,

H3-4,

μ,

μ,

D1-2

D1-2

Calyx or dimorphic
afferent

Efferent

Dimorphic and/or
bouton afferent

Fig. 2. Schematic illustration of type I (left) and type II (right) hair cell are shown with primary afferent and efferent neurons. Calyx or dimorphic afferents (gray fibers) envelop most of the basolateral surface of the type I hair cell and bouton and/or dimorphic afferents innervate the type II hair cell (gray fibers). Efferent axons arising from the brainstem contact the external surface of calyx afferent and
make direct contact with the basolateral surfaces of type II hair cell (green fiber). Synaptic vesicles are tethered to the synaptic ribbons
and release glutamate to trigger action potentials in primary afferent neurons. Efferent neurons modulate afferent neural responses.
Possible targets of pharmacological agents include AMPA, NMDA, KA, H3-4, GABAA-B, μ-opioid, D1-2, nACh, mACh, CGRP, enkephalin, and substance P receptors in the postsynaptic membranes of vestibular afferent fibers. AMPA: α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid, NMDA: N-methyl-D-aspartic acid, KA: kainic acid, H3-4: histamine 3-4, GABAA-B: γ-amino butyric acidA-B, D12: dopamine 1-2, nACh: nicotinic acetylcholine, mACh: muscarinic acetylcholine, CGRP: calcitonin gene-related protein.

Glutamate interacts with ionotropic receptors such as α-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), Nmethyl-D-aspartic acid (NMDA), and kainic acid (KA) as well
as metabotropic receptors such as metabotropic glutamate receptor 1-8 (mGluR1-8) [1,6]. Ionotropic and metabotropic
glutamate receptors are located on the vestibular primary afferent dendrites. These receptors mediate the input signals
from vestibular hair cells and also between primary afferents
and second order vestibular nuclei neurons (see below).
AMPA is a major glutamate receptor in the inner ear. The
AMPA response to glutamate produces a postsynaptic increase in intracellular cations including especially Na+ postsynaptically; these cations thus play a functional role in AMPA-mediated depolarization of vestibular afferent neurons [7].
Immunohistochemical studies have suggested that AMPA receptor subunits GluR1, GluR2-3, and GluR4 are expressed
in mammalian vestibular hair cells and calyx afferents [3,7].
The application of a specific AMPA/KA antagonist (1.5 mM
DNQX) to the mouse vestibular afferents blocked AMPA responses [7]. The neurons of the vestibular nuclei also express

AMPA EAA receptors. Popper, et al. [8] used immunohistochemistry in the vestibular nuclei of the chinchilla and found
ionotropic AMPA receptor subunits (GluR2-3) in the most neurons, (GluR1) in some neurons, and (GluR4) in the fewest number of neurons.
There is evidence in support of the presence of the NMDA
receptors on both vestibular hair cells and afferent neurons.
The NMDA receptor (NMDAR) subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D are reportedly expressed in rat vestibular afferent neurons [6]. Electrophysiological studies have suggested that the application of
NMDA antagonists [2-amino-5-phosphonopentanoic acid
(AP5) and 7-chloro-kynurenic acid (7ClKyn)] decreased spontaneous spike discharge in vestibular afferents [9]. In addition,
an electrophysiological study using whole-cell patch clamp
methods in the brainstem reported NMDA receptors contribute to afferent synaptic transmission in the medial vestibular
nucleus (MVN) of the rat [10]. These studies suggest that
NMDA receptors contribute to afferent neurotransmission in
both the peripheral and central vestibular system.
www.ejao.org 127
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Evidence for KA glutamate-receptors in the vestibular system is far less compelling, and glutamate affinity at ionotropic
KA receptors seems to be low. There are five KA receptor subunits (GluR5-7 and KA1-2); however, GluR5, GluR6, KA1,
and KA2 were only immunochemically expressed in mammalian vestibular ganglia [6]. Several pharmacological studies have suggested that KA receptors like other glutamate receptors act during afferent neurotransmission in mammalian
vestibular neurons. Trimetazidine, a potent antagonist of KA
receptor, blocked kainate-induced excitatory responses in the
rat vestibular afferent neurons [11]. AMPA/KA receptor antagonists, CNQX and NBQX, were delivered to the interstitial fluids of the inner ear through perilymphatic perfusion
and the effect on vestibular compound action potentials using
linear vestibular sensory evoked potentials (VsEPs) showed
VsEP response amplitudes were significantly reduced [12].
Evidence for metabotropic glutamate receptors in the vestibular pathways is far less compelling, with a limited number of
studies. Numerous studies have shown that the afferents innervating vestibular hair cells are triggered by responses to the
activation of glutamate receptors, and glutamate is a major afferent neurotransmitter at both peripheral and central afferent
synapses.
ACh receptors
The primary neurotransmitter of vestibular efferent synapses is acetylcholine [13,14]. In mammals including humans,
the activity of choline acetyltransferase (ChAT), which synthesizes ACh, and acetylcholinesterase (AChE), which inactivates ACh, was found in numerous bouton terminals at the
basal surface of the vestibular hair cells [13,15]. Two major
classes of ACh receptors found in the vestibular neuroepithelium are nicotinic ACh receptor (nAChR) and muscarinic
ACh receptor (mAChR). Over the last decade, Holt and his
colleagues have focused on addressing the function of the
vestibular efferent system and reported that vestibular efferent neurons produce both excitation and inhibition of vestibular responses in animals [13,14,16]. Their findings indicate
that efferent-mediated inhibition results from the activation
of α9α10 nACh receptors on type II vestibular hair cells and
direct efferent-mediated excitation of vestibular afferents is
mediated by mACh (mAChR1, 3, 5) and/or nACh receptors
(α4, α6, and β2) [14].
nACh receptors are ionotropic receptors (i.e., ligand-gated
ion channels) composed of diverse subunits: α3, α5-7, α9α10,
and β2-4 in the vestibular end organs as well as α2-7 and
β2-4 in the vestibular afferent neurons [13,14]. Based on their
inherent signaling mechanisms, nAChR-mediated responses
are faster than mAChR-mediated responses. Most nAChRs
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control the membrane permeability to cations especially Ca2+
ions [17] and when activted lead to membrane depolarization
and excitation of vestibular afferents. However, α9α10 nACh
receptors when activated increase Ca2+ entry into the cell, which
in turn activates Ca2+-dependent K+ (SK) channels. This produces membrane hyperpolarization, inhibition of neurotransmitter release and a reduction in the excitatory drive on primary afferents [14].
In addition to nACh receptors, mACh receptors are metabotropic receptors (i.e., G-protein-coupled receptors) and its receptor subunits (m1-5) are expressed in mammalian vestibular end organs and Scarpa’s ganglion [13,18]. Because of the
G-protein-coupled receptor signaling mechanism, mAChRmediated responses should follow relatively slower kinetics
than nAChRs. Despite the slow kinetics, mACh receptors have
been the target of vestibular suppressants (e.g., scopolamine).
Whole-cell patch clamp recordings of rat vestibular afferent
neurons showed that the mAChR agonist, oxotremorine-M,
significantly reduced outward polarizing K+ current called
“M-current,” causing depolarization and excitation of the neurons [19]. Its action was blocked by atropine, an mAChR antagonist, thus suggesting the presence of mAChRs on vestibular
afferent neurons. Recently using in vivo recordings, pharmacological reduction of M-current was shown to significantly alter peripheral vestibular afferent responses suggesting that efferent control of mAChRs may provide a means to modulate
primary afferent response characteristics [20].
In the vestibular nuclei, specific nAChR and mAChR subunits were not clearly identified. Even in the vestibular efferent neurons of brainstem, ChAT (responsible for the synthesis of ACh) is found only in some of the vestibular efferent
neurons [13] suggesting that some of these neurons may not
be mediated by nAChR and mAChR. Intracellular recordings of rat MVN have shown that nACh and mACh receptor
agonists produced membrane depolarization [21]. Extracellular recordings in all four major vestibular nuclei (i.e., medial,
lateral, inferior, and superior) of the rat vestibular nuclear
complex have indicated that nACh and mACh receptor agonists (carbachol and muscarine) increased spontaneous firing
rates and established that the effect of ACh agonists was highest in the MVN [22]. These studies indicate that both nACh
and mACh receptors are present and influence the excitability
of the mammalian vestibular nucleus neurons.
GABA receptors
The role of GABA in the vestibular system has been widely
debated, but a clear consensus has not been reached. GABA
receptors are divided into three types [23]: 1) GABAA receptor is an ionotropic receptor controlling a ligand-gated Cl-
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ion channel, 2) GABAB receptor is a metabotropic receptor
which interacts with Gi to inhibit adenylyl cyclase, upregulates
K+ channels, and downregulates Ca2+ channels, and 3) GABAC
receptor is a transmitter-gated Cl- channel but is not likely expressed in the vestibular system. Meza [24] and her research
group completed a considerable amount of work studying
mechanisms of GABA and its receptors in the vestibular sensory neuroepithelium. GABA synthesizing enzymes, L-glutamate decarboxylase (GAD) and GABA transaminase (GABA-T) are present as well as GABAA receptor-subunits γ1, γ2,
and γ3 are expressed in mammalian vestibular hair cells and
Scarpas’s ganglion [24]. These early findings were interpreted
as indicating that GABA may function as an afferent neurotransmitter in vestibular hair cells. However, this hypothesis
has not received convincing support. The presence of GABA
in vestibular epithelia is highly variable across species especially within hair cells. GABA-like immunoreactivity in efferent endings of the mammal was reported in the squirrel monkey but not rat or guinea pig and in the bird GABA labeling
was reported for the pigeon with weak labeling in the chicken
[25]. Electrophysiological studies also showed that the application of GABA agonists and antagonists had no direct effect
on the vestibular afferents [26]. These investigators plausibly
argued that GABA is not the neurotransmitter in the afferent
synapse, but may be a facilitator of glutamate release.
Rather than being a primary afferent transmitter, GABA
may have a modulatory role being co-released by efferent neurons and serve to modulate afferent activity in both the vestibular and auditory systems rather than act as the principal
hair cell transmitter driving sensory discharge patterns [13].
The mechanism of GABA action remains unclear, but it seems
to be involved to some extent in modulating Ca2+ signalling
mediated by inhibition of Ca2+ channels presynaptically and/
or activation of Cl- channels. Thus, it may indirectly reduce
neurotransmitter release presynaptically to disfacilitate postsynaptic cells [13,26].
Central vestibular nuclei are known to receive potent inhibitory inputs mediated by GABAA and GABAB receptors.
These GABAergic inputs arise primarily from commissural fibers of vestibular nuclei and cerebellum [5]. GABAA receptor
agonists including diazepam, lorazepam and clonazepam as
well as GABAB receptor agonists, baclofen, are the most widely used benzodiazepines and these act in the central vestibular
sensory pathways [27,28].
Histamine receptors
Histamine and its four receptors (H1, H2, H3, and H4) have
been identified in the vestibular sensory pathway: H1, H2,
and H3 receptors in the vestibular hair cells [29]; H3 and H4

receptors in the vestibular afferents [30,31]. All histamine receptors are metabotropic, with four different G-protein coupled
receptors acting through a second messenger intracellularly.
Evidence for histamine receptors in the vestibular system suggests that they may perform an important role in the control of
vestibular function.
Even though H1-3 receptors are expressed and their activation induces an influx of Ca2+ in vestibular hair cells, intracellular recordings of guinea pig vestibular hair cells have
shown that H3 receptors may mediate a notably larger increase in Ca2+ permeability (larger influx of Ca2+) compared to
H1 and H2 receptors [29]. Recently, H4 antagonist JNJ7777120
has been studied in Scarpa’s ganglion of the rat and electrophysiological recordings showed reversible inhibitory effects
elicited by the H4 receptor antagonist without subsequent excitatory action [31]. However, this effect may not be shared
by central vestibular nucleus neurons. The findings suggest
that H4 receptors mediate an excitatory action in vestibular
primary afferent neurons. Histamine also modulates the neural activities of the second order neurons in the vestibular nuclei and its various effects on the vestibular nuclei have been
reported in several electrophysiological studies. Dimaprit, a
selective H2 receptor agonist, produced an excitatory action
on rat MVN neurons, and its effect was blocked by ranitidine,
a selective H2 receptor antagonist, blocked its effect [32]. Betahistine (strong H3 receptor antagonist and weak H1 receptor agonist), produced a weak excitatory action, but significantly reduced the excitatory effect elicited by histamine on
the MVN neurons [32,33]. Thus, the effectiveness of histamine receptor antagonists on motion sickness, vertigo and dizziness can be explained by their action in reducing the excitatory actions in the mammalian vestibular nuclei and/or in the
vestibular periphery.
Opioid peptide receptors
The opioid receptors preferentially activated by the enkephalins largely comprise three receptor subtypes (μ-, k-, and
δ-receptors; G-protein coupled receptors) based on their pharmacological characteristics [34]. In addition to three major
receptor subtypes, the opioid-like orphan (ORL1) receptor is
another member of the opioid receptor family and is specifically activated by nociceptin. Enkephalins and opioid receptors were found in the vestibular sensory pathway: μ- and kopioid receptors in the vestibular hair cells and afferent neurons;
δ-opioid and ORL1 receptors in the MVN neurons [4,13,35].
Opioid peptides may be candidates for modulating synaptic
transmission in the vestibular afferent neurons. Whole-cell
patch clamp recordings of amphibian vestibular hair cells
showed that vestibular afferents were excited by μ-receptor
www.ejao.org 129
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agonists at the postsynaptic level (postsynaptic activation of
afferent neurons) and inhibited by k-receptor agonists at the
presynaptic level (inhibition of hair cells), reducing Ca2+ currents in the hair cells [36]. This study suggests that the vestibular afferents are regulated by the complex of opioid receptors. Electrophysiological data from mammalian MVN
neurons indicated that the δ-opioid receptor agonists inhibited rotation- and glutamate-induced firing rates [37] and ORL1
receptor agonists also inhibited the spontaneous discharge
rates [35]. These results suggest that enkephalins modulate
afferent transmission at both the peripheral and the central
vestibular levels.
Dopamine receptors
Dopamine receptors have been divided into two families:
a D1-like family of dopamine receptors including D1 and D5
as well as a D2-like family including D2, D3, and D4 (all Gprotein coupled receptors) [38]. Several findings support a
possible involvement of dopamine as a modulator of excitatory neurotransmission at postsynaptic afferent terminals [38,39].
In the mammalian vestibular neuroepithelium, immunochemical evidence has indicated that dopamine D1 and D2 receptors
are expressed in both type I and type II vestibular hair cell
membranes [40]. Pharmacological studies using extracellular
recordings showed that frog vestibular afferents were excited
by EAA agonists and the excitation was suppressed by co-administration of D1 or D2 agonists [39]. This result suggests
that the responses of D1 and D2 receptors act not only to
modulate glutamate receptors postsynaptically, but also may
have a protective function in the vestibular dendrites. In the
vestibular nuclei, guinea-pig MVN neurons were depolarized
only by D2 agonists; D1 receptors were not involved, suggesting the presence of D2 receptors in the mammalian MVN
[41]. In clinical applications, dopaminergic receptor antagonists such as prochlorperazine, promethazine, and domperidone [27] might exert a modulatory action on vestibular afferent neurons.
CGRP receptors
Immunochemical studies found that ChAT and CGRP probably co-exist in vestibular efferent neurons [13,42]. Electrophysiological data confirmed the function of CGRP receptor
and showed that CGRP released from efferent neurons increased vestibular afferent activities [3]. Sewell and Starr [43]
argued that CGRP released from efferent neurons produces
an increase in spontaneous discharge rate and this increases
the probability of excitatory postsynaptic potentials. Recently,
mice with loss of αCGRP gene (-/-) showed a significant reduction in Vestibular Ocular Reflex (VOR) gain, suggesting
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CGRP dependent effects in peripheral and/or central vestibular pathways [42]. Taken together, the results of these studies
regarding CGRP suggest that efferent fibers making contact
with both calyx afferents and type II hair cells contain CGRP
and CGRP may exert modulatory effects on ACh receptors to
increase the excitability of peripheral vestibular afferents.
Immunocytochemistry studies have reported the presence
of substance P in mammalian vestibular hair cells and Scarpa’s ganglion [3,4,44] and investigated the coexistence of substance P and CGRP in the rat vestibular end organs using immunocytochemistry. Usami, et al. [44] revealed three different
types of immunoreactivities localized within as well as beneath the sensory epithelia in rats. Since most immunoreactivity data clearly indicate that CGRP is associated with efferent
fibers, the finding of substance P also supports the coexistence of
the two and suggests a possible role for substance P in modulating the peripheral vestibular system.

Conclusion
The current review of the literature reveals that basic research on the pharmacological targets of drugs and medications has provided many answers to questions about the biochemical, molecular and functional nature of neural signaling
in the vestibular sensory pathways. If we are to understand
the action of drugs and medications, we must first understand the target receptors through which drugs and medications act to produce clinical outcomes. A considerable amount
of effort has been carried out to identify neurotransmitters
and modulators in the vestibular system using in vitro animal
preparations. Medications work by mimicking, suppressing
or otherwise altering these normal signaling processes. One
may speculate and infer that the lessons learned from study
of target processes and mechanisms, although often discovered in vitro, also apply to drug actions in the intact animal.
However, in many cases particularly in the case of new and
promising medications, drug actions in the intact animal are
not fully understood. Therefore, developing reliable direct in
vivo assessment tools for the study of vestibular sensory pathways will be important to accurately quantify drug effects on
vestibular function. Clinically, in vivo research on vestibular
pharmacological targets may aid the development of more accurate and effective intervention strategies for the treatment
of dizziness and vertigo.
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